Brief: Pharmather Files FDA Pre-Ind Meeting Request For Ketamine In Parkinson’S Disease
08/12/2020 12:16
Dec 8 (Reuters) - Newscope Capital Corporation PHRM.CD :
* PHARMATHER FILES FDA PRE-IND MEETING REQUEST FOR KETAMINE
IN
PARKINSON’S DISEASE
Source text for Eikon: ID:nGNX3HhTS1
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application